The use of opioids to relieve dysponea in the palliative care setting.

Phase 3

• Conditions: Dyspnoea; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12606000269538
• Lead Sponsor: Repatriation General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-06-29
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Specialist relevant has assessed participant to have received maximal treatment (including reversing anaemia) • On stable medications for the previous 7 days• Participant has dyspnoea score greater than or equal to 2 on the Modified Medical Research Council dyspnoea scale • In the treating clinician's estimation, the participant has a prognosis of at least one month.• On stable oxygen needs.

Exclusion Criteria

Pregnancy, any chance of pregnancy, or breastfeeding• On regular opioid medications, including codeine preparations. • Confusion (MMSE<24/30)• AKPS score of <50• Uncontrolled nausea or vomiting.• True adverse reaction(s) or hypersensitivity to previous opioids.• A creatinine clearance of <15ml/min. • Gastrointestinal obstruction.• Concomitant use of Monoamine Oxidase Inhibitor(s) (MAOIs) in the last 2 weeks.• Past history of substance misuse• Unwilling or unable to complete study measures.

Study & Design

• Study Type: Interventional
• Study Design: Not specified